B7-H3 could act as potent new cancer vessel-specific carrier to deliver antiangiogenic agents, and could help predict the clinical outcome of using different targeted agents in the treatment of ccRCC [26, 27]. This evidence concerns the gene CD276 and nonpapillary renal cell carcinoma.